Published in Genetics and Environmental Business Week, September 4th, 2008
This month's feature article reviews the competing hypotheses around the cause of Alzheimer's disease including: the beta amyloid theory, tau hypothesis, the APOE4 and vascular theory, anti-inflammatories, memory enhancers, neuroprotection and mitochondrial boosters.
The issue also discusses leading therapies in development from the following companies: Accera, Allon Therapeutics (TSX: NPC), Amgen, Avera, Ceregene,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.